Evaluating the susceptibility to ceftazidime-avibactam in clinical isolates of and recovered from an apex medical hospital in north India.

BACKGROUND AND OBJECTIVES

We assessed the susceptibility of ceftazidime+avibactam (CZA/AVI) in and isolated from intensive care units of our hospital.

MATERIALS AND METHODS

Clinical samples from Jan 2022 to Dec 2023 at SKIMS Soura, were processed for the recovery of and . Susceptibility testing was done by disc diffusion (DD) method and minimum inhibitory concentration (MIC) for CZA/AVI and meropenem was assessed using E-test strips. Categorical agreement (CA), very major errors (VME), major errors (ME) and minor errors (mE) between DD and MIC were measured. Statistical analyses were performed using SPSS version 22.0.

RESULTS

A total of 111 and 81 were part of the study. Of these, 56.8% and 45.7% isolates were susceptible to CZA/AVI. MIC of CZA/AVI for ranged from 0.125 to ≥ 256 μg/ml and for it ranged from 0.032 to 128 μg/ml. CA was 97.29% between DD and E-Test for CZA/AVI in isolates, with a ME of 2.70%. For CA between DD and E-Test for CZA/AVI was 98.76% with a VME of 1.23%. MIC values of meropenem were higher than CZA/AVI even in sensitive isolates.

CONCLUSION

CZA/AVI shows good in-vitro activity against clinical isolates of and and can be part of empirical therapy for treating infections caused by these bacteria.